Anti-CD19 Antibody Selective B Cell Targeting for MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD20-based therapies for multiple sclerosis (MS) indiscriminately deplete B cells, leading to long-term immunosuppression, potential increased susceptibility to infections, and delayed recovery of immune function when treatment is discontinued.
Innovation Solution
The use of an anti-CD19 antibody, such as obexelimab, which selectively targets and reduces B cells without depleting them, thereby minimizing side effects and allowing for the restoration of protective immune function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD20-based therapy is used to treat multiple sclerosis, then MS symptoms are reduced, but B cells are indiscriminately depleted leading to long-term immunosuppression and increased susceptibility to infections
Solution Approach 1:
The invention segments the B cell population by targeting CD19 specifically, which is expressed on mature B cells but not on plasma cells or memory B cells. This selective targeting allows treatment of MS while preserving important subsets of B cells that provide protective immune functions, thereby reducing immunosuppression and infection susceptibility compared to anti-CD20 therapy that depletes all B cells.
Solution Approach 2:
The anti-CD19 antibody therapy applies different effects to different B cell subsets based on their CD19 expression levels. Mature B cells expressing CD19 are targeted for reduction, while plasma cells and memory B cells with lower or no CD19 expression are preserved. This local quality approach maintains protective immune functions while treating MS symptoms.
2Reliability
If anti-CD20 therapy is used to deplete B cells, then MS disease activity is reduced, but recovery of immune function takes months when treatment is discontinued
Solution Approach 1:
By segmenting the B cell population and selectively targeting only CD19-positive mature B cells, the therapy preserves memory B cells and plasma cells that can quickly replenish protective immune functions. When treatment is discontinued, these preserved cell populations can rapidly restore immune defense, reducing the months-long recovery period associated with anti-CD20 therapy.
Solution Approach 2:
The therapy temporarily discards (reduces) only the pathogenic mature B cells that drive MS disease activity, while preserving the protective B cell subsets. Upon discontinuation, the preserved memory B cells and plasma cells can quickly recover and repopulate the B cell compartment, enabling rapid restoration of immune function without the prolonged recovery seen with complete B cell depletion.
Data Source
AI summary
The present invention provides methods of treating and improving the symptoms of multiple sclerosis using an antibody or antigen-binding fragment thereof that specifically binds human CD19 (e.g., obexclimab).